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Abstract 
Background: Jaagsiekte sheep retrovirus (JSRV) causes a contagious lung cancer in sheep and goats that can be 
transmitted by aerosols produced by infected animals. Virus entry into cells is initiated by binding of the viral envelope 
(Env) protein to a specific cell‑surface receptor, Hyal2. Unlike almost all other retroviruses, the JSRV Env protein is also 
a potent oncoprotein and is responsible for lung cancer in animals. Of concern, Hyal2 is a functional receptor for JSRV 
in humans.
Results: We show here that JSRV is fully capable of infecting human cells, as measured by its reverse transcription 
and persistence in the DNA of cultured human cells. Several studies have indicated a role for JSRV in human lung 
cancer while other studies dispute these results. To further investigate the role of JSRV in human lung cancer, we used 
highly‑specific mouse monoclonal antibodies and a rabbit polyclonal antiserum against JSRV Env to test for JSRV 
expression in human lung cancer. JSRV Env expression was undetectable in lung cancers from 128 human subjects, 
including 73 cases of bronchioalveolar carcinoma (BAC; currently reclassified as lung invasive adenocarcinoma with a 
predominant lepidic component), a lung cancer with histology similar to that found in JSRV‑infected sheep. The BAC 
samples included 8 JSRV DNA‑positive samples from subjects residing in Sardinia, Italy, where sheep farming is preva‑
lent and JSRV is present. We also tested for neutralizing antibodies in sera from 138 Peruvians living in an area where 
sheep farming is prevalent and JSRV is present, 24 of whom were directly exposed to sheep, and found none.
Conclusions: We conclude that while JSRV can infect human cells, JSRV plays little if any role in human lung cancer.
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Background
Jaagsiekte sheep retrovirus (JSRV) causes a contagious 
lung cancer in sheep called ovine pulmonary adenocar-
cinoma (OPA). Virus is secreted into lung fluid that can 
be aerosolized by coughing or sneezing allowing virus 
transmission to other animals [1]. The disturbing finding 
that human cells express a functional receptor for JSRV 
entry [2, 3], and histologic similarities between OPA and 
human lung cancers, including bronchioalveolar car-
cinoma (BAC) and other adenocarcinomas, has led to 
a search for a possible role for JSRV or related viruses 
in human lung cancer [4–12]. Of further concern, the 
envelope (Env) protein of JSRV is a potent oncoprotein 
and expression of Env alone in lungs of mice and sheep 
results in disease similar to that caused by the intact virus 
in sheep [13, 14]. Thus, JSRV is fully competent to induce 
lung cancer without the need for extensive virus replica-
tion and insertional activation of cellular oncogenes, as is 
seen in other retroviral cancers such as those induced by 
the murine leukemia retroviruses.
Several studies have addressed the possible role of JSRV 
in human lung cancer with mixed results. In an exten-
sive initial study of human lung cancer specimens from 
around the world, De las Heras et  al. [4] used a rabbit 
polyclonal antiserum against JSRV Gag proteins to per-
form an immunohistochemical analysis of formalin-fixed 
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paraffin-embedded lung tumor tissue. The authors found 
positive cytoplasmic staining of tumor cells in 30% of 129 
BAC specimens, 26% of 65 other adenocarcinomas, and 
2 of 7 large cell carcinomas. No staining was observed 
for 21 nontumor lung lesions, four normal lung tissues, 
23 adenocarcinomas from other organs and a cell line 
expressing a human endogenous retrovirus. These results 
suggested widespread involvement of JSRV in human 
lung cancer. However, two other groups found no evi-
dence for JSRV by PCR of DNA or RNA extracted from 
similar formalin-fixed paraffin-embedded lung tumor 
specimens [5, 6]. Samples included 26 BAC and 25 other 
adenocarcinoma specimens in one study [5] and 18 BAC 
and 6 other lung tumors in the other [6]. Both of these 
studies had reasonable positive controls and controls to 
ensure the quality of the DNA extracted from the fixed 
tissue. In addition, the positive results in the initial study 
[4] were called into question by additional reports indi-
cating that the polyclonal antiserum used in the ini-
tial study showed cross-reactivity with an endogenous 
human retroviral protein, leading to false positive results 
[7], and that no additional evidence of retroviral infection 
could be found in the lung cancer specimens that stained 
positive by the JSRV Gag antiserum [8].
In other positive studies, Morozov et  al. [9] detected 
JSRV DNA by nested PCR in blood of Africans from 
Nigeria and Cameroon, but not in a set of only 4 BAC 
specimens from patients from Russia and Germany. In 
the case of the blood samples, 28% were positive using 
one primer set, 11% using a second set, and 0% using a 
third primer set, indicative of technical issues in JSRV 
detection. Rocca et  al. [10] reported that JSRV was fre-
quently found in paraffin sections of BAC specimens 
from lung cancer patients in Sardinia (91% positive), 
where sheep farming is prevalent and the sheep are 
known to be infected with JSRV, but was infrequently 
found in patients with BAC from the Campania region 
(10% positive), where sheep farming is absent. JSRV was 
detected by nested PCR of JSRV gag DNA sequences in 
formalin-fixed paraffin-embedded tissues. However, 54% 
of normal lung specimens from Sardinia were also posi-
tive for JSRV DNA, showing that the presence of JSRV 
DNA was not well correlated with lung cancer. A more 
recent study found evidence for JSRV Env expression 
in human tissue arrays by immunostaining with JSRV 
Env monoclonal antibodies (Mabs) and by PCR analysis 
for JSRV gag and env DNA [11]. Unfortunately, original 
tumor samples were not available to definitively corrobo-
rate these results, and the interpretation of these results 
is problematic (see “Discussion”). Most recently, a high-
throughput sequencing approach found no evidence for 
JSRV in five human lung adenocarcinomas [12]. While 
this would provide a definitive method for detecting 
JSRV involvement in human lung cancer, the high cost of 
this approach limits its application to small numbers of 
lung cancer subjects.
To help resolve the role of JSRV in human lung cancer, 
we used highly specific mouse monoclonal antibodies 
(Mab) for immunohistochemical detection of the JSRV 
Env protein in fixed tissue sections [15], reasoning that 
detection of this viral oncoprotein in human lung cancer 
would be a sensitive and accurate indicator of a biological 
role for JSRV in human lung cancer. As shown previously, 
a mixture of two anti JSRV Env Mabs could readily detect 
JSRV in lungs of sheep from the USA, Peru, Spain, Kenya, 
and South Africa, showing that these Mabs could detect 
many wild strains of JSRV [15]. Human lung cancer sam-
ples analyzed in the current study include BAC and other 
lung cancer specimens, mostly from the United States, 
and Sardinian lung cancer samples that tested positive 
for JSRV DNA by nested PCR [10]. All of the lung can-
cer samples tested negative for JSRV Env expression by 
immunohistochemistry using the Mabs or a rabbit anti-
JSRV Env antiserum. Furthermore, we show that JSRV 
virus is able to infect cultured human cells, and that our 
Mabs could detect JSRV Env expression in human cells 
if present. Nor could we find virus-neutralizing antibod-
ies directed against the JSRV Env protein in 138 human 
subjects from the Central Sierra region of Peru who live 
in an area where sheep infected with JSRV are common. 
Together our results indicate that JSRV plays little if any 
role in human lung cancer.
Results
Lack of JSRV Env expression in lung cancer specimens 
from the United States
A set of 53 BAC and 50 other lung cancer samples from 
lung cancer patients seen at the MD Anderson Cancer 
Center were analyzed for expression of JSRV Gag and Env 
proteins by Mab and polyclonal rabbit antiserum staining 
of fixed tumor-bearing lung tissue [Table 1; BAC samples 
1–53 and other lung cancer (LCA) samples 1–50]. We 
focused on analysis of BAC samples because this histo-
logical classification is thought to most closely resemble 
the type of cancer seen in sheep infected with JSRV. Note 
that the currently accepted lung cancer classification 
that most closely corresponds to BAC is lung invasive 
adenocarcinoma with a predominant lepidic component 
with and without mucinous features [16, 17]. However, 
because the lung cancer samples analyzed here were col-
lected and histologically classified before this revision, we 
have kept the older terminology. The human lung can-
cers arose in patients 33–84 years of age, of both sexes, 
of White, Black, and Hispanic ethnicities, and who cur-
rently smoked, formerly smoked, or who never smoked. 
All of the human lung cancer specimens were completely 
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Table 1 Epidemiologic data and JSRV immunohistochemistry results for lung cancer patients seen at MD Anderson and Fred 
Hutchinson Cancer Centers
Human 
subject 
code
Ethnicity Sex Age Pack-years
Residence 
State/ 
COUNTRY
Smoker 
status
Tumor 
histology
JSRV MA 
(Gag) 
antiserum
JSRV SU 
(Env) 
antiserum
JSRV 
Env 
Mabs
BAC-01 W F 72 0 Texas Never BAC neg neg neg
BAC-02 B M 51 75 Texas Former BAC pos neg neg
BAC-03 W F 63 Texas BAC pos neg neg
BAC-04 W F 78 20 Texas Former BAC pos neg neg
BAC-05 W F 50 0 Louisiana Never BAC pos neg neg
BAC-06 W F 50 0 Louisiana Never BAC neg neg neg
BAC-07 W F 66 30 Texas Former BAC pos neg neg
BAC-08 W F 77 0 Florida Never BAC neg neg neg
BAC-09 W M 63 156 Texas Former BAC pos neg neg
BAC-10 W M 77 0 Louisiana Never BAC neg neg neg
BAC-11 W F 67 22 Texas Former BAC neg neg neg
BAC-12 W M 79 46 Colorado Former BAC neg neg neg
BAC-13 H M 64 5.6 Texas Former BAC neg neg neg
BAC-14 W M 64 80 Mississippi Current BAC pos neg neg
BAC-15 W F 77 0 Texas Never BAC neg neg neg
BAC-16 W M 68 0 Louisiana Never BAC neg neg neg
BAC-17 W M 70 30 Texas Former BAC neg neg neg
BAC-18 W M 63 45 Nebraska Former BAC neg neg neg
BAC-19 W F 77 0 Texas Never BAC neg neg neg
BAC-20 B M 49 15 Texas Current BAC neg neg neg
BAC-21 W F 66 25 Texas Former BAC pos neg neg
BAC-22 W F 76 40 Texas Former BAC neg neg neg
BAC-23 W M 47 40 Texas Current BAC neg neg neg
BAC-24 W M 68 45 South Carolina Former BAC neg neg neg
BAC-25 W F 66 45 Texas Former BAC pos neg neg
BAC-26 W F 60 0 Texas Never BAC pos neg neg
BAC-27 W M 62 5.25 Texas Former BAC neg neg neg
BAC-28 W M 76 25 Louisiana Former BAC pos neg neg
BAC-29 W M 63 88 Texas Current BAC neg neg neg
BAC-30 W F 74 30.75 Arizona Former BAC neg neg neg
BAC-31 W F 56 0 Texas Never BAC neg neg neg
BAC-32 W M 53 11.1 Texas Current BAC neg neg neg
BAC-33 W F 69 18 Louisiana Former BAC neg neg neg
BAC-34 W M 64 0 Missouri Never BAC pos neg neg
BAC-35 W F 58 20 Texas Former BAC neg neg neg
BAC-36 W F 62 15 Texas Former BAC neg neg neg
BAC-37 W F 49 34 Texas Current BAC neg neg neg
BAC-38 W F 76 20.5 Texas Former BAC pos neg neg
BAC-39 W F 39 0 Texas Never BAC pos neg neg
BAC-40 W F 61 0 Texas Never BAC neg neg neg
BAC-41 W F 66 0.25 Texas Former BAC neg neg neg
BAC-42 W F 74 0 Mississippi Never BAC neg neg neg
BAC-43 W M 69 49 Texas Current BAC pos neg neg
BAC-44 W F 41 0.1 New York Former BAC neg neg neg
BAC-45 W M 83 0 Texas Never BAC neg neg neg
BAC-46 B F 67 4.5 Texas Former BAC pos neg neg
BAC-47 W M 70 30 Texas Former BAC pos neg neg
BAC-48 W F 76 20.5 Texas Former BAC neg neg neg
BAC-49 W M 66 30 Arkansas Former BAC neg neg neg
BAC-50 W M 71 0 Texas Never BAC neg neg neg
BAC-51 H M 77 21 ECUADOR Former BAC pos neg neg
BAC-52 B F 45 0.2 Texas Former BAC neg neg
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Table 1 continued
Human 
subject 
code
Ethnicity Sex Age Pack-years
Residence 
State/ 
COUNTRY
Smoker 
status
Tumor 
histology
JSRV MA 
(Gag) 
antiserum
JSRV SU 
(Env) 
antiserum
JSRV 
Env 
Mabs
BAC-53 W F 75 30 Texas Former BAC neg neg
BAC-54 W M 52 Washington Current BAC neg
BAC-55 W F 69 Washington Former BAC neg
BAC-56 W M 78 Washington Former BAC neg
BAC-57 W M 67 Washington Current BAC neg
BAC-58 W M 58 Washington Current BAC neg
BAC-59 W F 68 Washington Former BAC neg
BAC-60 W M 70 Washington Former BAC neg
BAC-61 W F 77 Washington Never BAC neg
BAC-62 W F 90 Washington Former BAC neg
BAC-63 W M 73 Washington Former BAC neg
LCA-01 B M 68 37.5 Texas Former Squamous neg neg neg
LCA-02 W M 59 132 Alabama Former Squamous neg neg neg
LCA-03 W M 70 76.5 Oklahoma Current Squamous neg neg neg
LCA-04 W M 60 26 Texas Former Squamous neg neg neg
LCA-05 W M 33 17 Texas Current Adenocarcinoma neg neg neg
LCA-06 W F 79 36 Texas Former Adenocarcinoma neg neg
LCA-07 W F 62 28.5 Louisiana Current Squamous neg neg neg
LCA-08 W F 64 33 Georgia Former Adenocarcinoma pos neg neg
LCA-09 W M 49 0 Texas Never Adenocarcinoma neg neg neg
LCA-10 W M 63 80 Texas Former Squamous neg neg neg
LCA-11 W M 70 80 Michigan Former Squamous neg neg neg
LCA-12 B M 60 8.5 Louisiana Former Squamous neg neg neg
LCA-13 W M 72 84 Texas Current Squamous neg neg neg
LCA-14 H M 57 66 Texas Former Adenocarcinoma neg neg neg
LCA-15 W F 77 90 Texas Former Squamous neg neg neg
LCA-16 W M 55 29.25 Nevada Former Squamous neg neg neg
LCA-17 W M 62 96 Arkansas Current Adenocarcinoma neg neg neg
LCA-18 W F 46 32 Texas Current Adenocarcinoma neg neg neg
LCA-19 W M 80 0.8 Texas Former Adenocarcinoma neg neg neg
LCA-20 W F 71 39.75 Texas Current Squamous neg neg neg
LCA-21 W F 61 74 Oklahoma Former Squamous neg neg neg
LCA-22 W M 78 75 Florida Former Adenocarcinoma neg neg neg
LCA-23 W M 75 50 Alabama Former Squamous neg neg neg
LCA-24 B F 70 0 Texas Never Adenocarcinoma pos neg neg
LCA-25 W F 73 26.5 Kentucky Current Squamous neg neg neg
LCA-26 W F 68 52 Texas Current Squamous neg neg neg
LCA-27 W F 47 20 Iowa Current Adenocarcinoma neg neg neg
LCA-28 W M 48 49.5 Michigan Former Adenocarcinoma pos neg neg
LCA-29 W M 72 28 Texas Former Squamous neg neg neg
LCA-30 W M 61 40 Texas Current Squamous neg neg neg
LCA-31 W M 74 82 Texas Former Adenocarcinoma neg neg neg
LCA-32 W F 68 0 Texas Never Adenocarcinoma pos neg neg
LCA-33 W F 84 0 Texas Never Adenocarcinoma neg neg neg
LCA-34 W M 79 24.5 Texas Current Adenocarcinoma neg neg neg
LCA-35 W F 67 17 Colorado Former Squamous neg neg neg
LCA-36 W M 76 33.75 Texas Former Adenocarcinoma neg neg neg
LCA-37 W M 74 129 Louisiana Former Squamous neg neg neg
LCA-38 W M 64 50 Oklahoma Current Squamous neg neg neg
LCA-39 W M 82 63 Texas Current Adenocarcinoma neg neg neg
LCA-40 W M 58 45 Texas Former Squamous neg neg neg
LCA-41 W F 59 56 Texas Former Squamous neg neg neg
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negative for JSRV Env and SU (the extracellular domain 
of the Env protein) staining performed by using a mix-
ture of two highly-specific anti-JSRV-Env mouse Mabs 
or a rabbit SU (extracellular domain of Env) antiserum 
(Table 1). In contrast, lung cancer specimens from sheep 
infected with JSRV and from mice exposed to an AAV 
vector that expresses JSRV Env were accompanied by 
readily detectable JSRV Env expression. Because the Env 
protein of JSRV is the sole active oncogene in JSRV, these 
findings indicate that JSRV was not responsible for the 
lung cancers in these patients.
In contrast, we observed positive JSRV Gag matrix 
(MA) protein staining of many BAC samples (18 
of 51  =  35%, Table  1) and some LCA samples (6 of 
49 =  12%, Table  1), similar to the initial study showing 
a relatively high incidence of JSRV Gag expression (30%) 
in lung cancer specimens from around the world [4]. We 
interpret these data as indicating spurious staining by the 
JSRV Gag MA protein antiserum, as previously described 
[7]. Importantly, none of these Gag-positive samples 
stained positive when using the anti-JSRV Env Mabs or 
the rabbit anti-JSRV Env polyclonal antiserum.
We also tested for JSRV Env expression in a set of 10 
BAC and 5 other adenocarcinoma samples from newly-
diagnosed patients participating in a Fred Hutchinson 
Cancer Research Center study (Table  1; BAC samples 
54–63 and LCA samples 51–55). These lung cancer spec-
imens were freshly frozen, sectioned in a cryostat, and 
the sections were placed on slides and fixed using para-
formaldehyde in phosphate-buffered saline. All of the 10 
BAC and 5 adenocarcinoma specimens were completely 
negative for JSRV Env Mab staining, while control posi-
tive sheep and mouse tumors stained in parallel were 
strongly positive. Again, because the Env protein of JSRV 
is the active oncogene in JSRV, these findings indicate 
that JSRV played no role in the lung cancers of these 
patients.
Lack of JSRV Env expression in lung cancer samples 
from Sardinia
Ten of eleven (91%) lung cancer (BAC) specimens from 
patients living on the Italian island of Sardinia, where 
sheep farming is prevalent and the sheep are known 
to be infected with JSRV, were previously found posi-
tive for JSRV DNA by nested PCR, suggesting a role for 
JSRV in lung cancer in this region [10]. In contrast, only 
1 of 10 (10%) of BAC specimens from patients living in 
the Campania region of Italy, where sheep farming is 
absent, were found positive for JSRV DNA [10]. We ana-
lyzed BAC specimens from eight JSRV PCR-positive and 
two JSRV PCR-negative Sardinians, and OPA specimens 
from 3 Sardinian sheep, for JSRV Env expression. Histo-
logic staining of all samples was performed in parallel to 
control for any variables in the staining procedure. The 
tumor specimens were formaldehyde fixed and paraffin 
embedded. All of the human lung cancer specimens were 
completely negative for Env Mab staining while all three 
of the sheep samples were strongly positive (see Fig. 1 for 
images of the three sheep samples and one representative 
human tumor sample), indicating a lack of JSRV involve-
ment in the human lung cancer etiology despite the 
JSRV-positive PCR results.
Table 1 continued
Human 
subject 
code
Ethnicity Sex Age Pack-years
Residence 
State/ 
COUNTRY
Smoker 
status
Tumor 
histology
JSRV MA 
(Gag) 
antiserum
JSRV SU 
(Env) 
antiserum
JSRV 
Env 
Mabs
LCA-42 W M 72 126 Texas Former Squamous neg neg neg
LCA-43 W F 54 48 North Carolina Current Adenocarcinoma pos neg neg
LCA-44 W M 57 45 Missouri Former Adenocarcinoma pos neg neg
LCA-45 W M 77 0 Louisiana Never Adenosquamous neg neg neg
LCA-46 W F 58 38 Texas Current Adenocarcinoma neg
LCA-47 W F 76 99.75 Texas Former Adenocarcinoma neg neg neg
LCA-48 W M 74 15 Virginia Former Squamous neg neg neg
LCA-49 W M 61 50 Texas Former Adenocarcinoma neg neg neg
LCA-50 B F 67 4.5 Texas Former Adenocarcinoma neg neg neg
LCA-51 W M 68 Washington Former Adenocarcinoma neg
LCA-52 W M 68 Washington Current Adenocarcinoma neg
LCA-53 W M 57 Washington Former Adenocarcinoma neg
LCA-54 W M 71 Washington Never Adenocarcinoma neg
LCA-55 W M 68 Washington Former Adenocarcinoma neg
Lung cancer samples obtained at the MD Anderson Cancer Center (BAC-1 to 53 and LCA-1 to 50) were collected between January 1986 and December 2004, and 
those at the Fred Hutchinson Cancer Research Center (BAC-54 to 63 and LCA-51 to 55) were collected between October 1994 and February 1999. Ethnicity: W White, B 
Black, H Hispanic; Pack years, number of packs of cigarettes smoked per day × number of years the person has smoked, neg negative, pos positive. Never smoker status 
and positive JSRV MA (Gag) staining are highlighted in bolditalic. Absence of an entry in the results columns indicate the test was not performed
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JSRV Env expression in cultured human cells can be 
detected by Mab staining
We considered the possibility that the JSRV Env Mabs 
might not detect JSRV Env expression in human cells 
because of human-specific protein modifications that 
might interfere with Mab binding. To test for this pos-
sibility, human 293 cells were transfected with plasmids 
that expressed JSRV Env by using either a CMV promoter 
(pCIneoJenv) or an SV40 promoter (pSX2Jenv). Next, 
immunostaining was performed using the JSRV Env 
Mabs followed by a secondary antibody conjugated to the 
green dye, Alexa Fluor 488. As a positive control, rat 208F 
fibroblasts that stably express JSRV Env were analyzed 
in parallel. The human 293 cells transfected with either 
JSRV Env expression plasmid exhibited bright but het-
erogeneous immunostaining, typical of transiently trans-
fected cells, which was not seen when only the secondary 
antibody was used (Fig.  2). The JSRV-Env-expressing 
rat cells showed a more homogeneous staining pattern 
(Fig.  2), typical of stably transduced cells. These results 
show that the JSRV Env Mab is capable of detecting JSRV 
Env expression in human cells.
JSRV virus can infect human cells
It is known that JSRV Env can mediate entry of retrovi-
ral vectors into human cells [2, 3]. Entry is mediated by 
virus binding to the cell-surface protein Hyal2, which is 
a functional receptor for retroviral vectors bearing JSRV 
Env in sheep and human cells, but not in mouse cells 
for example [2]. However, it is not known whether there 
are post-entry restrictions to JSRV infection in human 
cells that might block virus infection, and if so, might 
explain the absence of JSRV Env expression in human 
lung cancer. To address this issue, we generated infec-
tious JSRV virus and tested for virus entry and conver-
sion of the viral RNA genome into DNA in SSF sheep 
skin fibroblasts and in several human cell lines, includ-
ing the human bronchial epithelial cell line IB3 [18]. IB3 
cells were made by immortalization of primary human 
bronchial epithelial cells by expression of SV40 T anti-
gen, and retain many of the biochemical characteris-
tics of normal lung epithelial cells [18], and thus have 
characteristics more like the natural lung epithelial cell 
targets for JSRV oncogenesis. JSRV DNA was present 
in DNA extracted from the sheep fibroblasts and all of 
the human cell lines exposed to live JSRV virus, but was 
not present in DNA of sheep or human cells exposed 
to heat-inactivated virus or to culture medium alone 
(Fig.  3). JSRV DNA was not found in NIH 3T3 mouse 
cells exposed to live JSRV virus (Fig.  3), as expected 
because these cells do not express a functional cell-entry 
receptor for JSRV. Viral DNA was detected in sheep and 
Sheep 77 Sheep 78
Sheep 97 Mouse Human 18211
400 μm 40 μm 100 μm 
100 μm 100 μm 100 μm 
Sheep 78
Fig. 1 Histological analysis of lung tissue from three Sardinian sheep with OPA, from a mouse with JSRV Env‑induced lung tumors, and from a 
representative Sardinian lung cancer patient. Histological staining, as described in “Methods”, was performed at the same time for all tissues shown. 
Scale bars are shown at the bottom of each panel
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in all of the human cells at 3 and 8 days after exposure 
of the cells to live JSRV virus, showing that viral DNA 
persisted during culture of the cells, and indicating but 
not proving that the virus was integrated into cellular 
DNA. Together, these results show that JSRV is able to 
infect human cells, as measured by persistence of JSRV 
DNA in the genomic DNA of several cultured human 
cell lines exposed to live JSRV virus, and indicate that 
a human-specific block to infection is not responsible 
for the absence of JSRV infection in human lung cancer 
patients.
Lack of neutralizing antibodies against JSRV in Peruvians 
living in areas coinhabited by JSRV infected sheep
Immunodeficient mice receiving an intranasal admin-
istration of a viral vector that expresses the JSRV Env 
protein rapidly died from widespread JSRV Env-induced 
lung cancer, while immunocompetent mice subjected to 
the same treatment rarely developed tumors [13]. The 
immunocompetent mice developed high-titer antibod-
ies against the JSRV Env protein that were capable of 
neutralizing a viral vector coated with JSRV Env [13], 
and that presumably played a role in clearance of JSRV 
Jenv Mab + 2° Ab 2° Ab only
208F/LJenvSN
cells
293 cells +
pCIneoJenv
plasmid
293 cells +
pSX2Jenv
plasmid
Fig. 2 JSRV Env Mabs bind to human 293 cells expressing the JSRV Env protein. Human 293 cells were transiently transfected with the JSRV Env‑
expression plasmids pCIneoJenv, which contains the JSRV Env coding region cloned into the pCIneo expression plasmid (Promega, Madison, WI), 
or pSX2Jenv [2]. JSRV Env expression is driven by a CMV promoter in pCIneoJenv, and by a Moloney murine leukemia virus (MoMLV) promoter in 
pSX2Jenv. The 208F/LJenvSN cells are 208F rat fibroblasts transduced with the LJenvSN retroviral vector, which contains the JSRV Env coding region 
cloned into the LXSN retroviral vector [41], and Env is expressed from the MoMLV promoter in LXSN. For analysis, the adherent cells were suspended 
using EDTA (no trypsin), centrifuged onto slides, fixed with formaldehyde, and subjected to immunostaining. The secondary (2°) antibody was a 
goat anti‑mouse IgG (H + L) conjugated to Alexa Fluor 488 (a green‑fluorescent dye) obtained from Invitrogen. Env expression is detected in all of 
these cell types by the JSRV Env Mabs
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Env-expressing lung tumor cells. To explain our inabil-
ity to detect JSRV Env expression in human lung cancer, 
we hypothesized that JSRV might be capable of infecting 
humans, but that the resulting immune response clears 
infected lung cells and prevents lung cancer initiation 
and/or progression.
To address this possibility, we tested for such immune 
responses in 138 men, women and children from the 
Central Sierra region of Peru who live in an area where 
sheep infected with JSRV are common (~2% annual mor-
tality and 4–6% morbidity from JSRV infection), and 
24 of whom were involved in occupations that involved 
direct exposure to sheep (sheep herders, n  =  6; vet-
erinary technicians, n = 6; sheep farmers, n = 4; veteri-
narians, n = 4; and slaughterhouse workers, n = 4). We 
tested for anti-JSRV Env neutralizing antibodies by meas-
uring inactivation of a retroviral vector bearing the JSRV 
Env protein (LAPSN(PJ4) [2]), which is on the surface 
of JSRV virions, and is the protein responsible for onco-
genic transformation of infected cells. The human serum 
samples were mixed with the LAPSN(PJ4) vector, which 
encodes human placental alkaline phosphatase, and the 
titer of the vector was measured using human HTX cells 
as targets (see “Methods”). 135 of the 138 Peruvian serum 
samples we tested were unable to inactivate the JSRV 
vector (antibody titer <2), while sera from an immuno-
competent mouse exposed to an AAV vector encoding 
JSRV Env [13] inactivated the vector (titer >200). Three 
of the Peruvian serum samples showed titers between 3 
and 30. Because it has been reported that human com-
plement can neutralize some retroviruses in the absence 
of virus-specific antibodies [19–21], we next tested 
for virus inactivation by these three serum samples 
after heat-inactivation of the sera (56  °C for 30  min) to 
destroy complement activity. Heat-inactivation reduced 
the neutralizing activity of these three serum samples 
HTX IB3 3T3 SSF SSF 293
M M − HI LV − HI LV − HI LV − HI LV − HI LV − HI LVN
C
1
N
C
2
500
100
Size 
(bp)
IB3 SSF 
M − HI LV − HI LV
500
100
Size 
(bp) N
C
1
N
C
2 SSF 293
− LV − LV
HTX
− LVM 
Cellular DNA harvested 8 days after virus exposure
Cellular DNA harvested 3 days after virus exposure
Fig. 3 PCR detection of JSRV sequences in the genomic DNA of cells exposed to live JSRV virus (LV), heat‑inactivated virus (HI) or culture medium 
alone (−). PCR amplification procedures are described in “Methods”. M indicates a 1 kb Plus DNA Ladder (Thermo Fisher) with select band sizes indi‑
cated. The expected JSRV amplification product (arrows) has a size of 502 bp, which is clearly visible in the live virus (LV) lanes of all cell types except 
for the NIH 3T3 cells, which lack a functional cell‑surface receptor for JSRV. This band is absent in all of the heat inactivated (HI) virus and negative 
control (−) lanes. The top two panels show an analysis of cellular DNA harvested 3 days after virus exposure, and this experiment was repeated 
once with identical results. The bottom two panels show an analysis of cellular DNA harvested 8 days after virus exposure, and this experiment was 
performed once
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to undetectable levels (titer <2). In contrast, heat inac-
tivation of sera from four sheep infected with JSRV and 
from one immunocompetent mouse that had received an 
intranasal administration of a vector encoding JSRV Env 
had no effect on the neutralizing activity of these sera 
(data not shown). In conclusion, we were unable to detect 
a virus-neutralizing antibody response directed against 
JSRV Env in any of these Peruvian subjects, indicating a 
lack of JSRV infection of these subjects.
Discussion
JSRV utilizes the cell-surface protein Hyal2 to gain entry 
into cells [3]. A functional Hyal2 receptor is expressed 
on sheep, human, monkey, canine, bovine, and rabbit 
cells, but not on mouse, rat or hamster cells [2]. Here we 
show for the first time that the JSRV RNA genome can 
be reverse transcribed into DNA and persist in human 
cells, indicating the absence of restriction factors that 
might block JSRV infection at a post-entry step in virus 
infection. Furthermore, the JSRV Env protein alone can 
transform a variety of cultured cell types [3, 22–24] and 
induce lung cancer in mice [13] and sheep [14]. Note that 
Hyal2 is not required for oncogenic transformation by 
JSRV, because lung tumors can be induced by expression 
of JSRV Env alone in mice, which express a Hyal2 protein 
that does not bind JSRV Env and cannot mediate JSRV 
entry into cells [13, 15]. However, we find no evidence for 
JSRV involvement in human lung cancer.
We do know that while expression of JSRV Env in 
lungs of immunodeficient Rag2-knockout mice that lack 
mature T and B cells can cause rapid development of 
tumors and death, immunocompetent mice are resist-
ant to lung cancer induction by the same treatment [13] 
(although this result appears to be dependent of the 
strength of the promoter that drives JSRV Env expres-
sion [25]). In contrast, the sheep genome contains many 
endogenous copies of retroviral elements related to 
JSRV, and sheep are relatively immunotolerant of JSRV 
presumably because of expression of proteins related to 
those of JSRV by these endogenous elements [26]. These 
considerations suggest that the best place to look for pos-
sible JSRV involvement in human lung cancer would be 
in lung cancer patients who have had extensive exposure 
to JSRV-infected sheep and who are immunodeficient 
because of genetic or environmental factors, including 
infection by immunosuppressive agents such as HIV. For 
the present, however, it appears that JSRV plays little if 
any role in lung cancer in humans.
Initially, we were very excited to test for expression of 
JSRV Env protein in human lung cancer specimens from 
Sardinia, Italy, where sheep farming is prevalent, JSRV is 
present in these sheep, and PCR analysis indicated the 
presence of JSRV in the human lung cancer specimens 
from Sardinia but not from Campania where sheep farm-
ing is absent [10]. However, we find no evidence for JSRV 
Env expression in the Sardinian lung cancer samples. To 
understand the discrepancy between the positive PCR 
results and our negative Mab staining results, we note 
several issues with the PCR analysis and its interpreta-
tion. First, the authors state that the PCR primers they 
used were specific for endogenous JSRV, which is pre-
sent in multiple copies in sheep. But the acknowledged 
source of these primer sequences was a report from 
Cousens et al., in which the JSRV primers used were spe-
cifically designed to not amplify sheep endogenous DNA 
sequences [27]. Indeed, National Center for Biotechnol-
ogy Information BLAST analysis (performed 17 Decem-
ber 2016) of the JSRV sequence identified by Rocca et al. 
in human specimens [10] most closely matches exog-
enous JSRV sequences. Thus it is a surprise that normal 
liver and normal lung samples from Sardinians not suf-
fering from lung cancer were also PCR-positive for JSRV. 
The authors then went on to argue that these results sug-
gested the presence of JSRV as an endogenous virus pre-
sent in the genomes of the Sardinian people. We think 
this possibility is very unlikely (but could be easily tested 
by genomic sequencing, for example), and instead sug-
gest either the PCR results represent false positives, or 
that the presence of JSRV-infected sheep DNA in food 
or in the environment is responsible for the positive PCR 
results. We believe the negative JSRV-Env Mab and rabbit 
antiserum staining definitively rules out a role for JSRV in 
the Sardinian lung cancer samples analyzed here.
Previous reports have shown that human serum can 
inactivate a variety of retroviruses, including Molo-
ney murine leukemia virus, feline leukemia virus, and 
New Zealand black mouse xenotropic murine leukemia 
virus [19–21]. While the initial studies indicated that 
the viruses were lysed by complement in the absence of 
antibody involvement, later studies have indicated that 
natural antibodies against the Galα1–3Gal sugar epitope 
present on cell-surface proteins of all mammals, with the 
exception of old-world primates (including humans), are 
required for complement lysis of various retroviruses [28, 
29]. Regardless, the virus neutralizing activity in human 
serum has been proposed as a natural barrier to human 
infection by retroviruses and other viruses present in 
animals. Thus, it is surprising that most of the Peruvian 
serum samples we tested (98%) were unable to neutral-
ize the retroviral vector bearing the JSRV Env protein, 
even in the absence of heat treatment of the sera to inac-
tivate complement. The LAPSN(PJ4) vector used in the 
neutralization assay was produced from mouse retroviral 
packaging cells [2], and the Galα1–3Gal sugar epitope 
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is added to cell-surface proteins made by mouse cells. 
Previously, it has been shown that the JSRV Env protein 
stabilizes retroviral vectors against lung surfactant, cen-
trifugation, and freeze–thaw cycling compared to other 
retroviral Env proteins [30]. These considerations sug-
gest that JSRV is more resistant than other animal ret-
roviruses to antiviral restrictions in humans that operate 
prior to virus entry into cells.
In contrast to results reported here, others have 
claimed evidence for the presence of JSRV in human lung 
cancer as determined by using the same anti-JSRV Env 
Mabs we used here [11]. We disagree with this conclu-
sion based primarily on the data presented in Fig.  1 of 
that report, which purports to show positive Mab stain-
ing of human lung cancer tissue. We argue that none 
of the human tissue staining presented in Fig.  1 closely 
resembles the Mab staining shown for JSRV-induced 
sheep tumors in panel R of that Figure. In our experi-
ence, the mixture of anti-JSRV Env Mabs that we used 
here provides robust staining of JSRV-induced tumors in 
sheep and JSRV Env-induced tumors in mice, and allows 
single tumor cells to be easily identified ([15] and Fig. 1 of 
the current report). There is no need for a grading system 
for the staining results that was used in Ref. [11]. Indeed, 
the staining of the human lung cancer tissue sections [11] 
resembles background staining we occasionally see with 
polyclonal mouse anti-JSRV Env antibodies (data not 
shown). Secondly, although JSRV env and gag sequences 
were detected in some human tissue samples and in 
pooled tissue arrays, this data is unconvincing. Detection 
of trace amounts of specific DNA sequences by highly-
sensitive PCR techniques is notorious for yielding false-
positive results, especially when the testing lab or nearby 
labs already have plasmids or PCR amplification products 
bearing very high numbers of copies of the sequence to 
be detected.
Previous work has shown that the mixture of the two 
anti-JSRV Env Mabs used in the current report can read-
ily detect lung cancer caused by JSRV in sheep from the 
USA, Peru, Spain, Kenya and South Africa [15], and in 
this report we demonstrate detection of JSRV in lung 
cancer of sheep from Sardinia, Italy (Fig.  1). The Mabs 
are also known to detect Env expression in tumors 
caused by a closely related virus, enzootic nasal tumor 
virus (ENTV) [15]. Immunohistochemical staining of 
JSRV-infected tumor cells by the Mabs is clear and une-
quivocal, and the Mabs provide an unlimited reagent for 
diagnostic testing of the involvement of JSRV and related 
viruses in lung and nasal tumors of sheep and goats. Here 
we show that these Mabs recognize JSRV Env expression 
on human cells as well, indicating that they will be useful 
in future studies of the possible involvement of JSRV and 
ENTV in human cancers.
Methods
Lung tumor specimens
Lung tumor specimens were obtained from stored mate-
rial from previous Institutional Review Board-approved 
studies. The current studies were performed with Institu-
tional Review Board approval from the Fred Hutchinson 
Cancer Research Center and the MD Anderson Cancer 
Center.
Immunohistochemistry
Lung cancer specimens were fixed in 10% formalin or 
2% paraformaldehyde in phosphate-buffered saline and 
were embedded in paraffin wax. The JSRV Env mono-
clonal antibodies (Mabs) used were an equal mixture of 
culture medium conditioned by the B3 and C9 mouse 
hybridoma cell lines [15]. For analysis, ~5  µm thick tis-
sue sections were deparaffinized, subjected to antigen 
retrieval, stained with Mabs, and counterstained with 
methyl green as previously described [15]. Control JSRV-
positive lung cancer specimens were obtained from 
sheep infected with JSRV or from mice with lung tumors 
induced by transfer and expression of JSRV Env to their 
lungs by using an AAV vector [13]. At least one positive 
control sample was analyzed in parallel with each batch 
of human lung cancer samples to be sure the immunohis-
tochemical staining succeeded.
Lung cancer specimens were also stained using rabbit 
polyclonal antiserum against the surface domain (SU) of 
the JSRV Env protein (kindly provided by the Moredun 
Research Institute, Edinburgh, Scotland), and a poly-
clonal antiserum against the matrix domain (MA) of 
the JSRV Gag protein (kindly provided by Massimo Pal-
marini) obtained by immunizing rabbits with a recombi-
nant protein consisting of the N-terminal domain of the 
JSRV Gag protein that was expressed in bacteria (Pro-
teintech). Lung sections were deparaffinized, subjected 
to antigen retrieval with citrate buffer pH 6.0 in a pres-
sure cooker, and stained following routine procedures as 
previously described [7, 31, 32]. Control JSRV-positive 
lung cancer specimens were obtained from sheep with 
naturally-acquired OPA. Control negative tissue sections 
were obtained from a dog with naturally-acquired lung 
adenocarcinoma. Pre-immune sera were collected before 
immunizations. Normal rabbit serum and immunohisto-
chemistry buffer were used as negative controls for anti-
serum staining.
Cell culture
293 human embryonic kidney cells [33, 34], 293T cells 
[35], HTX cells (a pseudodiploid subclone of HT-1080 
human fibrosarcoma cells (ATCC CCL-121) [36]), IB3 
immortalized human bronchial epithelial cells [18], 
and SSF-123 primary sheep skin fibroblasts (gift from 
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William Osborne, University of Washington, Seattle), 
were grown in DMEM with 10% FBS in a 10% CO2/air 
atmosphere at 37  °C. The identity and human origin of 
the 293, HTX and IB3 cell lines was confirmed by short 
tandem repeat (STR) polymorphism analysis performed 
by the University of Arizona Genetics Core. The experi-
mental STR data for these cell lines matched reference 
data for the 293 and HTX cell lines [37], and for the IB3 
cell line [38].
Detection of JSRV infection of human cells
Infectious JSRV was produced by calcium phosphate-
mediated transfection of 293T cells with a plasmid that 
contains a JSRV provirus driven by a human cytomeg-
alovirus (CMV) promoter, as previously described [39]. 
Briefly, cells were seeded at 3 ×  106 per 6-cm dish and 
20  h later were transfected with 5  μg pCMV2-JSRV21 
plasmid DNA per dish. The culture medium was changed 
6 h after transfection and 24 h after the medium change, 
the virus-containing medium was collected, centrifuged 
at 2700 × g for 10 min to remove cell debris, and was fil-
tered through 0.45-μm filters. Virus was stored at −80 °C.
For virus infection, cells were seeded in 6-well plates at 
5 × 105 per well (SSF, IB3 or HTX cells) or at 106 per well 
(293 cells). 20 h later, the cells were treated with 400 μl of 
medium containing live JSRV, heat inactivated JSRV (65 °C 
for 15 min) or no virus, all in the presence of 5 μg/ml Poly-
brene (to facilitate infection). One day after treatment, the 
culture medium was replaced with fresh medium and the 
cells were cultured for an additional 2–7 days.
For analysis of integrated JSRV proviral DNA, culture 
medium was removed and the cells were washed twice 
with phosphate-buffered saline. Cells were detached 
using trypsin, were pelleted in 1.5  ml centrifuge tubes, 
and genomic DNA was extracted by using QIAamp 
DNA mini kits (QIAGEN, catalog #51306), accord-
ing to the manufacturer’s instructions. Genomic DNA 
was quantified by using a Nanodrop ND-2000 UV–vis 
spectrophotometer (Thermo Fisher Scientific, Wilming-
ton, DE). Then 250  ng genomic DNA was used as tem-
plate to amplify JSRV specific fragments by using Dream 
Taq DNA polymerase (Thermo Fisher). Sense primer-I 
5′TGGGAGCTCTTTGGCAGAAGCC3′ and reverse 
primer 5′CTGACGACTATGCGTTTGTCCC3′ were 
used to amplify the first round product, with expected 
size of 527  bp. Then 0.5  µl of first-round amplification 
products were used as templates to amplify the 2nd 
round products, by using sense primer-II 5′GCCTAG-
GACAAGTACCTAAGCTC3′ and reverse primer 
5′CTGACGACTATGCGTTTGTCCC3′, with expected 
size of 502 bp. PCR products were resolved in 1% agarose 
gels with a 1 kb Plus DNA Ladder (Thermo Fisher) as a 
reference.
Virus neutralization assay
The ability of serum to neutralize the infectivity of virus 
bearing the JSRV Env protein was measured. The virus 
used was a retroviral vector encoding placental alkaline 
phosphatase that was packaged using Gag-Pol proteins 
from Moloney murine leukemia virus and Env protein 
from JSRV (LAPSN(PJ4)) [2]. Briefly, approximately 150 
infectious units of virus were mixed with various dilu-
tions of untreated or heat-inactivated (56 °C for 30 min) 
serum in a total volume of 40 µl, and the mixtures were 
incubated at 20  °C (room temperature) for 30  min. The 
serum–virus mixtures were then added to HTX human 
fibrosarcoma cells in 6-well plates seeded the day before 
at 5 × 104 cells per well. Infections were done in the pres-
ence of 4 µg/ml Polybrene. Two days after virus exposure, 
the cells were stained for alkaline phosphatase expres-
sion as described (Support Protocol 5) [40], and positive 
foci were counted. Antibody titers were expressed as the 
reciprocal of the highest dilution of serum that reduced 
the number of alkaline phosphatase-positive foci by 
≥50%.
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